Waldencast CFO Manfredi Exercises 79,289 RSUs

What Happened
Manfredi Manuel, Chief Financial Officer of Waldencast plc (WALD), reported the exercise/conversion of 79,289 derivative awards (RSUs) on July 30, 2026. The Form 4 shows an acquisition of 79,289 shares at $0.00 per share and a corresponding disposition of a derivative interest also reported at $0.00. No cash payment or sale proceeds are reported in the filing.

Key Details

• Transaction date: July 30, 2026 (filed with the SEC on August 7, 2026). The filing occurred 8 days after the transaction date (outside the typical 2-business-day Form 4 window).
• Amounts/prices: 79,289 RSUs exercised/converted → 79,289 shares; exercise/conversion price reported as $0.00.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes of note:
  • F1: These 79,289 RSUs represent accelerated vesting tied to Waldencast’s July 30, 2026 sale of its Obagi Medical business; effective on that date Manuel transitioned to lead Obagi Medical.
  • F2: Each RSU converts to one Class A ordinary share or an equivalent cash value at the plan administrator’s election.
  • F3: The RSUs originated from a 10/30/2024 grant of 118,933 RSUs that vested over three years; the 79,289 corresponds to the remaining unvested portion after the first tranche vested in 2025.

Context
This filing reflects accelerated vesting and conversion of RSUs tied to a corporate transaction (sale of a business) rather than an open-market buy or sell. Because RSUs are awards rather than market purchases, they do not necessarily signal a buy/sell sentiment; they document compensation conversion and the reporting of that event. The later filing date is informational—delays can result in disclosure late-filing flags but do not, by themselves, indicate misconduct.